| HOME >> MEDICINE >> TECHNOLOGY |
-- the Company's ability to enter into and successfully execute license
and collaborative agreements, if any;
-- the adequacy of the Company's capital resources and cash flow
projections, and the Company's ability to obtain sufficient financing
to maintain the Company's planned operations;
-- the adequacy of the Company's patents and proprietary rights;
-- the impact of litigation that has been brought against the Company and
its officers and directors and any proposed settlement of such
litigation;
-- the Company's ability to regain compliance with the NASDAQ's listing
qualifications; and
-- the other risks described under Certain Risks and Uncertainties
Related to the Company's Business, as contained in the Company's
Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements. There are a number of factors that could cause actual results
and developments to differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report on Form 10-K for 2006
and its most recent quarterly report on Form 10-Q.
CONTACT:
Nichol Harber
Genta Investor Relations
908-286-3980
Genta Incorporated
Selected Condensed Consolidated Financial Data
(In thousands, except per share data)
(Unaudited)
Three Months Ended Twelve Months Ended
December 31 December 31
2007 2006 2007 2006
Product sales - net $ 267 $ 117 $ 580 $ 708
Cost of goods sold
'/>"/>
| SOURCE Genta Incorporated Copyright©2008 PR Newswire. All rights reserved |